Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials
ABSTRACT Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a meta-a...
Gespeichert in:
| Veröffentlicht in: | Current medical research and opinion 2005-07, Vol.21 (7), p.1123-1130 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1130 |
|---|---|
| container_issue | 7 |
| container_start_page | 1123 |
| container_title | Current medical research and opinion |
| container_volume | 21 |
| creator | Catapano, Alberico Brady, William E. King, Thomas R. Palmisano, Joanne |
| description | ABSTRACT
Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a meta-analysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed.
Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14, 2004.
Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10 mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg) were compared with efficacy results from clinical trials of rosuvastatin 5 mg, 10 mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded.
Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg) through their highest doses (ezetimibe/simvastatin 10/80 mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20 mg and rosuvastatin 10 mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40 mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80 mg and rosuvastatin 40 mg, respectively.
Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies. |
| doi_str_mv | 10.1185/030079905X50642 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1185_030079905X50642</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68018502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-3a8af42be49bdedb64771049e469e66a88b2253dae167672e5cca13067d3c8723</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhiMEokvhzA1ZHLiF2o5jJ72hii9pJS4gcYsm9oR1ZceL7bRafgk_F0e7UFGppzm8z7yy56mql4y-ZaxrL2hDqep72n5vqRT8UbVhQjW16JR6XG3WtC5xe1Y9S-maUsa7vn9anTFJqZAd31S_t3ZvDQGXMdr5R43TZDXoAwkTwV-YrbcjEh1qMN7ONhUMDbm1eUeS9TeQMmQ7F8Dv4V8SQ1r-RpcEiMcMNczgDsmmtXkfgiuwgQxkisETJoh2pV-DIzlacOl59WQqA1-c5nn17cP7r1ef6u2Xj5-v3m1rLXiT6wY6mAQfUfSjQTNKoRSjokche5QSum7kvG0MIJNKKo6t1sAaKpVpdKd4c169OfbuY_i5YMqDt0mjczBjWNIgO1oOTVfw9T3wOiyxfCoNfHXQSskKdHGEdLlBijgN-2g9xMPA6LAaG-4ZKxuvTrXL6NHc8SdFBbg8AnaeQvRwG6IzQ4aDC3GKMGubhubh9v6_5R0W0ztdVN29_qHdP5pYt9s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>207995661</pqid></control><display><type>article</type><title>Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Catapano, Alberico ; Brady, William E. ; King, Thomas R. ; Palmisano, Joanne</creator><creatorcontrib>Catapano, Alberico ; Brady, William E. ; King, Thomas R. ; Palmisano, Joanne</creatorcontrib><description>ABSTRACT
Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a meta-analysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed.
Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14, 2004.
Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10 mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg) were compared with efficacy results from clinical trials of rosuvastatin 5 mg, 10 mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded.
Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg) through their highest doses (ezetimibe/simvastatin 10/80 mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20 mg and rosuvastatin 10 mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40 mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80 mg and rosuvastatin 40 mg, respectively.
Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/030079905X50642</identifier><identifier>PMID: 16004682</identifier><identifier>CODEN: CMROCX</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject><![CDATA[Anticholesteremic Agents - administration & dosage ; Anticholesteremic Agents - pharmacokinetics ; Anticholesteremic Agents - therapeutic use ; Azetidines - administration & dosage ; Azetidines - pharmacokinetics ; Azetidines - therapeutic use ; Cholesterol, LDL - blood ; Clinical Trials as Topic ; Drug Therapy, Combination ; Ezetimibe ; Fluorobenzenes - administration & dosage ; Fluorobenzenes - pharmacokinetics ; Fluorobenzenes - therapeutic use ; Humans ; Hypercholesterolemia ; Hypercholesterolemia - drug therapy ; Lipids ; Meta-analysis ; Pyrimidines - administration & dosage ; Pyrimidines - pharmacokinetics ; Pyrimidines - therapeutic use ; Rosuvastatin Calcium ; Simvastatin - administration & dosage ; Simvastatin - pharmacokinetics ; Simvastatin - therapeutic use ; Statin therapies ; Sulfonamides - administration & dosage ; Sulfonamides - pharmacokinetics ; Sulfonamides - therapeutic use ; Treatment Outcome]]></subject><ispartof>Current medical research and opinion, 2005-07, Vol.21 (7), p.1123-1130</ispartof><rights>2005 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2005</rights><rights>Copyright Librapharm Jul 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-3a8af42be49bdedb64771049e469e66a88b2253dae167672e5cca13067d3c8723</citedby><cites>FETCH-LOGICAL-c423t-3a8af42be49bdedb64771049e469e66a88b2253dae167672e5cca13067d3c8723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1185/030079905X50642$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1185/030079905X50642$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16004682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Catapano, Alberico</creatorcontrib><creatorcontrib>Brady, William E.</creatorcontrib><creatorcontrib>King, Thomas R.</creatorcontrib><creatorcontrib>Palmisano, Joanne</creatorcontrib><title>Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>ABSTRACT
Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a meta-analysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed.
Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14, 2004.
Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10 mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg) were compared with efficacy results from clinical trials of rosuvastatin 5 mg, 10 mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded.
Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg) through their highest doses (ezetimibe/simvastatin 10/80 mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20 mg and rosuvastatin 10 mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40 mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80 mg and rosuvastatin 40 mg, respectively.
Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.</description><subject>Anticholesteremic Agents - administration & dosage</subject><subject>Anticholesteremic Agents - pharmacokinetics</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Azetidines - administration & dosage</subject><subject>Azetidines - pharmacokinetics</subject><subject>Azetidines - therapeutic use</subject><subject>Cholesterol, LDL - blood</subject><subject>Clinical Trials as Topic</subject><subject>Drug Therapy, Combination</subject><subject>Ezetimibe</subject><subject>Fluorobenzenes - administration & dosage</subject><subject>Fluorobenzenes - pharmacokinetics</subject><subject>Fluorobenzenes - therapeutic use</subject><subject>Humans</subject><subject>Hypercholesterolemia</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>Lipids</subject><subject>Meta-analysis</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - pharmacokinetics</subject><subject>Pyrimidines - therapeutic use</subject><subject>Rosuvastatin Calcium</subject><subject>Simvastatin - administration & dosage</subject><subject>Simvastatin - pharmacokinetics</subject><subject>Simvastatin - therapeutic use</subject><subject>Statin therapies</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - pharmacokinetics</subject><subject>Sulfonamides - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kU1v1DAQhiMEokvhzA1ZHLiF2o5jJ72hii9pJS4gcYsm9oR1ZceL7bRafgk_F0e7UFGppzm8z7yy56mql4y-ZaxrL2hDqep72n5vqRT8UbVhQjW16JR6XG3WtC5xe1Y9S-maUsa7vn9anTFJqZAd31S_t3ZvDQGXMdr5R43TZDXoAwkTwV-YrbcjEh1qMN7ONhUMDbm1eUeS9TeQMmQ7F8Dv4V8SQ1r-RpcEiMcMNczgDsmmtXkfgiuwgQxkisETJoh2pV-DIzlacOl59WQqA1-c5nn17cP7r1ef6u2Xj5-v3m1rLXiT6wY6mAQfUfSjQTNKoRSjokche5QSum7kvG0MIJNKKo6t1sAaKpVpdKd4c169OfbuY_i5YMqDt0mjczBjWNIgO1oOTVfw9T3wOiyxfCoNfHXQSskKdHGEdLlBijgN-2g9xMPA6LAaG-4ZKxuvTrXL6NHc8SdFBbg8AnaeQvRwG6IzQ4aDC3GKMGubhubh9v6_5R0W0ztdVN29_qHdP5pYt9s</recordid><startdate>200507</startdate><enddate>200507</enddate><creator>Catapano, Alberico</creator><creator>Brady, William E.</creator><creator>King, Thomas R.</creator><creator>Palmisano, Joanne</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>200507</creationdate><title>Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials</title><author>Catapano, Alberico ; Brady, William E. ; King, Thomas R. ; Palmisano, Joanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-3a8af42be49bdedb64771049e469e66a88b2253dae167672e5cca13067d3c8723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Anticholesteremic Agents - administration & dosage</topic><topic>Anticholesteremic Agents - pharmacokinetics</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Azetidines - administration & dosage</topic><topic>Azetidines - pharmacokinetics</topic><topic>Azetidines - therapeutic use</topic><topic>Cholesterol, LDL - blood</topic><topic>Clinical Trials as Topic</topic><topic>Drug Therapy, Combination</topic><topic>Ezetimibe</topic><topic>Fluorobenzenes - administration & dosage</topic><topic>Fluorobenzenes - pharmacokinetics</topic><topic>Fluorobenzenes - therapeutic use</topic><topic>Humans</topic><topic>Hypercholesterolemia</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>Lipids</topic><topic>Meta-analysis</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - pharmacokinetics</topic><topic>Pyrimidines - therapeutic use</topic><topic>Rosuvastatin Calcium</topic><topic>Simvastatin - administration & dosage</topic><topic>Simvastatin - pharmacokinetics</topic><topic>Simvastatin - therapeutic use</topic><topic>Statin therapies</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - pharmacokinetics</topic><topic>Sulfonamides - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Catapano, Alberico</creatorcontrib><creatorcontrib>Brady, William E.</creatorcontrib><creatorcontrib>King, Thomas R.</creatorcontrib><creatorcontrib>Palmisano, Joanne</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Catapano, Alberico</au><au>Brady, William E.</au><au>King, Thomas R.</au><au>Palmisano, Joanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2005-07</date><risdate>2005</risdate><volume>21</volume><issue>7</issue><spage>1123</spage><epage>1130</epage><pages>1123-1130</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><coden>CMROCX</coden><abstract>ABSTRACT
Objective: Results of direct comparative studies between ezetimibe/simvastatin and rosuvastatin therapies have not been reported. Both of these treatment options offer significant reductions in LDL-C. To evaluate the lipid efficacy of each of these therapies relative to each other, a meta-analysis of data from 14 randomized, double-blind clinical trials that compared the effectiveness of two new options for cholesterol lowering was performed.
Data sources: PubMed, EMBASE and BIOSIS databases were searched up to March 14, 2004.
Methods of study selection: Efficacy results from clinical trials with the co-administration of ezetimibe 10 mg with simvastatin or with the ezetimibe/simvastatin combination product (ezetimibe/simvastatin 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg) were compared with efficacy results from clinical trials of rosuvastatin 5 mg, 10 mg, 20 mg, and 40 mg in patients with primary hypercholesterolemia. Trials in healthy patients, heterozygous familial hypercholesterolemia or combined hyperlipidemia, and pharmacokinetic trials were excluded.
Data extraction and synthesis: This analysis used pooled data for LDL-C, HDL-C, non-HDL-C, triglycerides, total cholesterol, apolipoprotein (apo) A-I, and apo B for the two therapies at their lowest doses (ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg) through their highest doses (ezetimibe/simvastatin 10/80 mg and rosuvastatin 40 mg), and estimated within-treatment percentage changes in these parameters. Percentage reductions from baseline in LDL-C for the pooled data were 46.2% and 41.8% for ezetimibe/simvastatin 10/10 mg and rosuvastatin 5 mg, respectively; 50.6% and 47.4% for ezetimibe/simvastatin 10/20 mg and rosuvastatin 10 mg, respectively; 55.9% and 52.1% for ezetimibe/simvastatin 10/40 mg and rosuvastatin 20 mg, respectively; and 59.7% and 58.5% for ezetimibe/simvastatin 10/80 mg and rosuvastatin 40 mg, respectively.
Conclusions: The results of this meta-analysis suggest greater LDL-C lowering with ezetimibe/simvastatin compared with rosuvastatin. These results need to be confirmed in a head-to-head comparison of both therapies.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>16004682</pmid><doi>10.1185/030079905X50642</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-7995 |
| ispartof | Current medical research and opinion, 2005-07, Vol.21 (7), p.1123-1130 |
| issn | 0300-7995 1473-4877 |
| language | eng |
| recordid | cdi_crossref_primary_10_1185_030079905X50642 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Anticholesteremic Agents - administration & dosage Anticholesteremic Agents - pharmacokinetics Anticholesteremic Agents - therapeutic use Azetidines - administration & dosage Azetidines - pharmacokinetics Azetidines - therapeutic use Cholesterol, LDL - blood Clinical Trials as Topic Drug Therapy, Combination Ezetimibe Fluorobenzenes - administration & dosage Fluorobenzenes - pharmacokinetics Fluorobenzenes - therapeutic use Humans Hypercholesterolemia Hypercholesterolemia - drug therapy Lipids Meta-analysis Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Rosuvastatin Calcium Simvastatin - administration & dosage Simvastatin - pharmacokinetics Simvastatin - therapeutic use Statin therapies Sulfonamides - administration & dosage Sulfonamides - pharmacokinetics Sulfonamides - therapeutic use Treatment Outcome |
| title | Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A30%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20altering-efficacy%20of%20ezetimibe%20co-administered%20with%20simvastatin%20compared%20with%20rosuvastatin:%20a%20meta-analysis%20of%20pooled%20data%20from%2014%20clinical%20trials&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Catapano,%20Alberico&rft.date=2005-07&rft.volume=21&rft.issue=7&rft.spage=1123&rft.epage=1130&rft.pages=1123-1130&rft.issn=0300-7995&rft.eissn=1473-4877&rft.coden=CMROCX&rft_id=info:doi/10.1185/030079905X50642&rft_dat=%3Cproquest_cross%3E68018502%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=207995661&rft_id=info:pmid/16004682&rfr_iscdi=true |